BioCryst Upgraded To Outperform

Symbols: BCRX
Share

Rodman & Renshaw has upgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) from Market Perform to Market Outperform with a $7 price target.

BioCryst Pharmaceuticals closed yesterday at $4.82.

Is AAPL a Buy, Sell or Hold? Click Here.


 
 
< Previous
Endo Pharmaceuticals Gets An Upgrade
Next >
Steelcase Upgraded To Buy
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust